New drug combination for slow-growing lymphoma that has returned
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing a combination of two drugs—pomalidomide (a pill that helps the immune system fight cancer) and obinutuzumab (an antibody that targets a protein on lymphoma cells). It's for people whose slow-growing lymphoma has come back or hasn't responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a slow-growing lymphoma that tests positive for CD20 (like follicular lymphoma, marginal zone lymphoma, or small lymphocytic lymphoma).
- Your lymphoma has come back or hasn't responded to at least one earlier treatment.
- You are generally able to take care of yourself (up to 2 on a 0-5 scale where 0 means fully active).
- Your blood counts are within safe limits (with some help allowed if needed).
- Your liver and kidney function are adequate, and you have at least one tumor that can be measured.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of pomalidomide, an antibody that targets a protein on B cells, and a steroid to treat slow-growing B-cell lymphomas. If you have not yet been treated and meet the health criteria, this could be an option to consider.
This trial tests a new vaccine medicine (EO2463) to treat indolent non-Hodgkin lymphoma (slow-growing lymphoma), either by itself or with other treatment. It may help your immune system recognize and attack lymphoma cells.
This study tests a new way to treat slow-growing non-Hodgkin lymphoma that has come back or not responded to other treatments. It combines special immune cells with a targeted therapy to try to destroy cancer cells.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
This trial tests three drugs together—pomalidomide, an anti-PD-1 antibody, and selinexor—to treat primary central nervous system lymphoma (a blood cancer in the brain) that has returned after previous treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
This trial tests a combination of two medications (obinutuzumab and CC-99282) for people with a type of lymphoma called follicular lymphoma that has not been treated before and is considered high-burden (meaning it is widespread or growing quickly). The goal is to see if this combination helps control the cancer.
Hear when a new Indolent Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.